middle.news

How Will Nyrada’s Xolatryp Perform in Upcoming Heart Attack Trial?

1:01pm on Tuesday 21st of October, 2025 AEDT Biotechnology
Read Story

How Will Nyrada’s Xolatryp Perform in Upcoming Heart Attack Trial?

1:01pm on Tuesday 21st of October, 2025 AEDT
Key Points
  • Phase I trial confirms strong safety profile for Xolatryp
  • Phase IIa trial planned for STEMI patients undergoing PCI
  • AU$8.25 million capital raised to support clinical and R&D activities
  • Collaborative study reinforces Xolatryp’s mitochondrial protective mechanism
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Nyrada (ASX:NYR)
OPEN ARTICLE